Concepedia

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Hendrik Borgmann, Nada Lallous, Deniz Özistanbullu, Eliana Beraldi, Naman Paul, Kush Dalal, Ladan Fazli, Axel Haferkamp, Pascale Lejeune, Artem Cherkasov,

European Urology · 2017 · 109 citations · 7 references

DOI

Concepts

References

7

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

James D. Joseph, Nhin Lu, Jing Qian et al. · Cancer Discovery · 2013 · 581 citations · Full text

, , +17

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Alexander W. Wyatt, Arun Azad, Stanislav Volik et al. · JAMA Oncology · 2016 · 384 citations · Full text

, , +17

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

Anu‐Maarit Moilanen, Reetta Riikonen, Riikka Oksala et al. · Scientific Reports · 2015 · 373 citations · Full text

, , +17

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Nada Lallous, Stanislav Volik, Shannon Awrey et al. · Genome biology · 2016 · 212 citations · Full text

, , +17

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

Karim Fizazi, Christophe Massard, Petri Bono et al. · The Lancet Oncology · 2014 · 194 citations · Full text

, , +13